|
pubmed:abstractText |
Cyclo-oxygenase-2 (COX-2), the key enzyme in the conversion of arachidonic acid to prostaglandins, is involved in critical steps of tumor onset and progression, and is a strong predictor of chemotherapy resistance and poor outcome in advanced ovarian cancer. To our knowledge, no data has been reported until now about the association between COX-2 status and response to different chemotherapy regimens.
|
|
pubmed:affiliation |
Gynecologic Oncology Unit, Catholic University, L,go Gemelli 8, 00168, Rome, Italy. gabriella.ferrandina@libero.it
|
